NEW YORK, Dec. 21, 2017 /PRNewswire/ -- The U.S. Judicial Panel on Multidistrict Litigation (JPML) is preparing to take up a a motion to transfer all federally-filed Onglyza lawsuits to a single U.S. District Court, which would allow pending and future claims to undergo coordinated discovery and other pretrial proceedings. (IN RE: ONGLYZA (SAXAGLIPTIN) AND KOMBIGLYZE XR (SAXAGLIPTIN AND METFORMIN) PRODUCTS LIABILITY LITIGATION, MDL No. 2809)
According to an Order dated December 15th, the Panel will hear Oral Arguments on the matter during its January 25th Hearing Session, which will be convened at 9:30 a.m. in Miami, Florida.
"Our Firm is representing a number of Onglyza lawsuit plaintiffs, and we continue to receive inquiries from individuals who developed heart failure and other cardiac problems allegedly related to treatment with Onglyza or Kombiglyze XR. As this litigation could eventually include hundreds of similar cases, it would likely benefit from centralization in single federal court," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is filing free legal reviews to individuals who were diagnosed with heart failure following treatment with Onglyza or Kombiglyze XR.
Onglyza and Kombiglyze XR are used in conjunction with diet and exercise to lower blood sugar levels in patients with Type 2 diabetes. Onglyza (saxagliptin) was approved by the U.S. Food & Drug Administration (FDA) in 2009, while Kombiglyze XR (saxagliptin and metformin) was cleared for sale in November 2010.
The FDA launched a safety review of all saxagliptin-containing drugs in February 2014, after a clinical trial called SAVOR-TMI suggested that the medications were associated with a 27% increase in hospitalizations for heart failure, as well as a higher risk of all-cause mortality. In April 2015, a panel of outside FDA advisers recommended that the prescribing information for Onglyza and Kombiglyze XR be updated to include heart failure as a possible side effect. The FDA ordered the drugs' manufacturers to modify the labels' "Warnings and Precautions" section in April 2016.
According to the JPML's December 15th Order, there are currently more than 40 lawsuits involving Onglyza and Kombiglyze XR pending in 24 separate federal jurisdictions. Plaintiffs claim that AstraZeneca and Bristol-Myers Squibb concealed information linking saxagliptin to an increased risk of heart failure and neglected to warn of its alleged potential to cause cardiac arrest, congestive heart failure and death.
In October 2011, a group of plaintiffs filed a motion with the JPML seeking transfer of all federally-filed Onglyza and Kombiglyze XR lawsuits to the U.S. District Court, Northern District of California, pointing out that pending claims put forth virtually identical legal and factual theories. The motion predicted that hundreds of similar lawsuits will be filed in the future and asserted that centralization in a single federal jurisdiction will serve the convenience of the parties, witnesses, counsel, and the judicial system.
Type 2 diabetes patients who were diagnosed with heart failure while using Onglyza or Kombiglyze XR could be entitled to compensation for medical bills, lost wages, pain and suffering and more. To obtain a free case evaluation, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
View original content with multimedia:http://www.prnewswire.com/news-releases/federal-judicial-panel-to-address-onglyza-lawsuit-consolidation-at-january-25th-hearing-bernstein-liebhard-llp-reports-300574575.html
SOURCE Bernstein Liebhard LLP